GLAUKOS GKOS
GLAUKOS Corp · NYSE · Surgical & Medical Instruments & Apparatus
$242.48+33.65%close on Oct. 29, 2026 · volume 5.4M · Yahoo Finance
Price, last 48 sessions
Our coverage
Nothing published yet.
Insider buying and selling
| Date | Insider | Trade | Shares | Avg. price | Value |
|---|---|---|---|---|---|
| Oct. 5, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sold 10b5-1 plan | 1,527 | $164.45 $163.93-$165.60 | $251,120 |
| Sept. 25, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sold 10b5-1 plan | 1,615 | $154.28 $151.70-$154.88 | $249,158 |
| Sept. 16, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sold 10b5-1 plan | 1,457 | $166.92 $163.20-$172.00 | $243,204 |
| Aug. 28, 2026 | Tomas Navratil CHIEF DEVELOPMENT OFFICER | Sold | 13,744 | $180.67 $180.25-$182.50 | $2.48 million |
| Aug. 19, 2026 | Gilbert H. Kliman director | Sold | 2,500 | $190.00 | $475,000 |
| Aug. 11, 2026 | Joseph E. Gilliam PRESIDENT & COO | Sold | 60,000 | $179.74 $178.89-$180.49 | $10.78 million |
| Aug. 7, 2026 | Alex R. Thurman SVP & CHIEF FINANCIAL OFFICER | Sold 10b5-1 plan | 20,000 | $180.13 | $3.60 million |
| July 31, 2026 | Leana Wen director | Sold | 525 | $167.63 | $88,006 |
Open-market purchases and sales reported on SEC Form 4 filed since July 24, 2026; grants, option exercises and shares withheld for tax aren't shown. A trade under a 10b5-1 plan was scheduled in advance. Where a filing was amended, the amendment's figures are shown.
Recent SEC filings
All 13 →Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedGlaukos Q3 2026 Net Sales Rise 58% to Record $211.0 Million; Non-GAAP EPS $0.47 Beats Consensus; 2026 Sales Guidance Raised to $775-$785 Million